SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Sepracor-Looks very promising

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: smh who wrote (3774)10/14/1999 9:24:00 AM
From: BMcV  Read Replies (1) of 10280
 
Nothing new here. Old friend Jordan Kimmel was Herb Greenberg's source for his comments on SEPR a couple of months ago. No point is disputing his arguments, as that has been done in surfeit, expect to point out that the shorts' story is getting old and is losing force. We'll see if there are any more sheep out there.

And on insider buying, there was that huge options exercise by TB last month, confirmed on Yahoo Club recently. Note he has changed "no insider ownership" to "no insider buying".

cnbc.com


"Jordan Kimmel, market strategist at First Montauk Securities, was this morning?s guest on Stock Pickers Club during Today?s Business and gave us three stocks he'd avoid.

Kimmel says his company looks for revenue growth, growth at a discount, and relative strength. Kimmel says the stocks he would avoid have low or slow growth, are trading at a premium, and are underperforming the market.

Review his three stocks picks below from his appearance on Today's Business.

Sepracor, Inc. {SEPR}
--there's slow to no revenue growth
--excessive valuation
--not making money, so its price-to-sales ratio is astronomical
--the FDA said the company provided misleading information regarding its R&D of new drugs
--there isn?t any insider buying."
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext